Evotec SE ( EVO ) shares rose on Wednesday following news of advancements in its strategic partnership with Bristol-Myers Squibb Company ( BMY ) , which is focused on developing a molecular glue-based pipeline.

Significant scientific advancements are broadening the pipeline of molecular glue degraders into fields beyond oncology, leading to a $50 million program-based payment for Evotec.

Evotec and Bristol Myers Squibb ( BMY ) began their strategic partnership in protein degradation in 2018.

In May 2022, the company extended and expanded its partnership with Bristol Myers Squibb ( BMY ) for another 8 years. In August this year, Evotec announced progress in its strategic partnership with Bristol Myers, as performance-based and program-based achievements trigger payments totaling $75 million.

Cord Dohrmann, Chief Scientific Officer of Evotec, expressed enthusiasm about the expanded partnership with Bristol Myers Squibb ( BMY ), highlighting its focus on addressing significant unmet medical needs beyond oncology.

This expansion also enhances the overall value of the deal through potential program-based milestones.

Also Read: Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

Evotec has significantly increased its efforts to develop innovative compounds from Bristol Myers Squibb’s top-tier library of cereblon E3 ligase modulators (CELMoDs).

The partnership continues to deliver on its goal by adding a diverse pipeline of novel molecular glue degraders for high-value targets, extending beyond oncology.

Dohrmann emphasized that the collaboration is creating an impressive pipeline of first-in-class products and looks forward to advancing their joint programs toward clinical validation for patient benefit.

Price Action: EVO shares are trading higher by 7.49% to $3.515 at last check Wednesday.

Read Next:

Bristol Myers’ German Partner Evotec Plans Layoffs, Cites ‘Challenging Revenues, Profitability’